Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Apr;69(4):641–647. doi: 10.1038/bjc.1994.125

Pharmacokinetics in melanoma-bearing mice of 5-dihydroxyboryl-6-propyl-2-thiouracil (BPTU), a candidate compound for boron neutron capture therapy.

R Verrijk 1, I J Smolders 1, R Huiskamp 1, P R Gavin 1, K H Philipp 1, A C Begg 1
PMCID: PMC1968811  PMID: 8142252

Abstract

Blood pharmacokinetics and tissue distribution of 5-dihydroxyboryl-6-propyl-2-thiouracil (BPTU), a boron carrier with postulated melanin-seeking properties for boron neutron capture therapy, were determined in C57/BL mice with subcutaneous pigmented or non-pigmented B16 melanomas. Borocaptate sodium (BSH) was used as a boron compound without melanin-seeking properties in a comparative biodistribution study in the same animal tumour models. Administration of single doses showed that BPTU was retained better in the pigmented B16 tumour than in the non-pigmented variant. BPTU was found in large concentrations in kidney and liver. Brain boron was approximately 10-fold lower than tumour boron. On a molar basis, BPTU demonstrated higher affinity for B16 tumours than BSH. Owing to solubility limits, tumour boron concentrations in this mouse study were too low for effective application of BNCT. However, the high tumour-to-blood and tumour-to-normal tissues ratios indicate that, with appropriate formulation, BPTU could be a promising candidate for clinical BNCT.

Full text

PDF
641

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen B. J., Coates A. S., McCarthy W. H., Mameghan H., Mishima Y., Ichihashi M. Thermal neutron capture therapy: the Japanese-Australian clinical trial for malignant melanoma. Basic Life Sci. 1989;50:69–73. doi: 10.1007/978-1-4684-5622-6_9. [DOI] [PubMed] [Google Scholar]
  2. Coderre J. A., Glass J. D., Fairchild R. G., Micca P. L., Fand I., Joel D. D. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res. 1990 Jan 1;50(1):138–141. [PubMed] [Google Scholar]
  3. Coderre J. A., Glass J. D., Fairchild R. G., Roy U., Cohen S., Fand I. Selective targeting of boronophenylalanine to melanoma in BALB/c mice for neutron capture therapy. Cancer Res. 1987 Dec 1;47(23):6377–6383. [PubMed] [Google Scholar]
  4. Coderre J. A., Joel D. D., Micca P. L., Nawrocky M. M., Slatkin D. N. Control of intracerebral gliosarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat Res. 1992 Mar;129(3):290–296. [PubMed] [Google Scholar]
  5. Coderre J. A., Slatkin D. N., Micca P. L., Ciallella J. R. Boron neutron capture therapy of a murine melanoma with p-boronophenylalanine: dose-response analysis using a morbidity index. Radiat Res. 1991 Nov;128(2):177–185. [PubMed] [Google Scholar]
  6. Fairchild R. G., Packer S., Greenberg D., Som P., Brill A. B., Fand I., McNally W. P. Thiouracil distribution in mice carrying transplantable melanoma. Cancer Res. 1982 Dec;42(12):5126–5132. [PubMed] [Google Scholar]
  7. Gabel D., Fairchild R. G., Larsson B., Börner H. G. The relative biological effectiveness in V79 Chinese hamster cells of the neutron capture reactions in boron and nitrogen. Radiat Res. 1984 May;98(2):307–316. [PubMed] [Google Scholar]
  8. Giuliano A. E., Cochran A. J., Morton D. L. Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol. 1982 Dec;9(4):442–447. [PubMed] [Google Scholar]
  9. Gregoire V., Begg A. C., Huiskamp R., Verrijk R., Bartelink H. Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. Radiother Oncol. 1993 Apr;27(1):46–54. doi: 10.1016/0167-8140(93)90043-8. [DOI] [PubMed] [Google Scholar]
  10. Hiratsuka J., Fukuda H., Kobayashi T., Karashima H., Yoshino K., Imajo Y., Mishima Y. The relative biological effectiveness of 10B-neutron capture therapy for early skin reaction in the hamster. Radiat Res. 1991 Nov;128(2):186–191. [PubMed] [Google Scholar]
  11. Ichihashi M., Sasase A., Hiramoto T., Funasaka Y., Hatta S., Mishima Y., Kobayashi T., Fukuda H., Yoshino K. Relative biological effectiveness (RBE) of thermal neutron capture therapy of cultured B-16 melanoma cells preincubated with 10B-paraboronophenylalanine. Pigment Cell Res. 1989 Jul-Aug;2(4):325–329. doi: 10.1111/j.1600-0749.1989.tb00212.x. [DOI] [PubMed] [Google Scholar]
  12. Jain R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987 Jun 15;47(12):3039–3051. [PubMed] [Google Scholar]
  13. Jara J. R., Aroca P., Solano F., Martinez J. H., Lozano J. A. The role of sulfhydryl compounds in mammalian melanogenesis: the effect of cysteine and glutathione upon tyrosinase and the intermediates of the pathway. Biochim Biophys Acta. 1988 Nov 17;967(2):296–303. doi: 10.1016/0304-4165(88)90023-2. [DOI] [PubMed] [Google Scholar]
  14. Madoc-Jones H., Wazer D. E., Zamenhof R. G., Harling O. K., Bernard J. A., Jr Clinical considerations for neutron capture therapy of brain tumors. Basic Life Sci. 1990;54:23–35. doi: 10.1007/978-1-4684-5802-2_3. [DOI] [PubMed] [Google Scholar]
  15. Mishima Y., Ichihashi M., Tsuji M., Hatta S., Ueda M., Honda C., Suzuki T. Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma-seeking compound. J Invest Dermatol. 1989 May;92(5 Suppl):321S–325S. doi: 10.1111/1523-1747.ep13076750. [DOI] [PubMed] [Google Scholar]
  16. Packer S., Coderre J., Saraf S., Fairchild R., Hansrote J., Perry H. Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine. Invest Ophthalmol Vis Sci. 1992 Feb;33(2):395–403. [PubMed] [Google Scholar]
  17. Slatkin D. N. A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain. 1991 Aug;114(Pt 4):1609–1629. doi: 10.1093/brain/114.4.1609. [DOI] [PubMed] [Google Scholar]
  18. Tjarks W., Gabel D. Boron-containing thiouracil derivatives for neutron-capture therapy of melanoma. J Med Chem. 1991 Jan;34(1):315–319. doi: 10.1021/jm00105a049. [DOI] [PubMed] [Google Scholar]
  19. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  20. Wheeler F. J., Griebenow M. L., Wessol D. E., Nigg D. W. Analytical modeling for neutron capture therapy. Strahlenther Onkol. 1989 Feb-Mar;165(2-3):186–188. [PubMed] [Google Scholar]
  21. Yamada K., Larsson B. S., Roberto A., Dencker L., Ullberg S. Selective incorporation of thiouracil into murine metastatic melanomas. J Invest Dermatol. 1988 Jun;90(6):873–876. doi: 10.1111/1523-1747.ep12462131. [DOI] [PubMed] [Google Scholar]
  22. Zha X., Ausserer W. A., Morrison G. H. Quantitative imaging of a radiotherapeutic drug, Na2B12H11SH, at subcellular resolution in tissue cultures using ion microscopy. Cancer Res. 1992 Oct 1;52(19):5219–5222. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES